Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Summary
This trial is an open-label, multi-center, dose escalation, dose expansion, and cohort expansion phase I/II clinical study of SYHX1903 in patients with relapsed/refractory hematologic malignancies. This trial aims to evaluate the safety, tolerance, pharmacokinetics, and preliminary antitumor activity of SYHX1903 in patients with relapsed/refractory hematologic malignancies.
Official title: A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Efficacy of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
312
Start Date
2021-12-29
Completion Date
2026-09-20
Last Updated
2021-09-24
Healthy Volunteers
No
Interventions
SYHX1903
SYHX1903 tablets, orally, qd